These immune checkpoint restoration through the use of monoclonal antibodies directed has profoundly increased the therapeutic index of anti-PD-1/PD-L1 therapies in many cancer types with particularly impressive responses observed in a subset of patients with non-small cell lung cancer (NSCLC) 6-10. The gene discussed is PDCD1; the disease is cancer.